Britain and America have established a landmark bilateral deal that will preserve no tariffs on British pharmaceutical exports entering the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has agreed to boost spending on pharmaceuticals through the NHS. This move secures that duties on these crucial products will remain at nothing for a timeframe of 36 months.
This development follows earlier statements to dramatically increase tariffs on patented pharmaceutical products, with increases discussed up to 100%.
"This arrangement between the United Kingdom bolsters the global environment for cutting-edge drugs and introduces long-overdue equity to U.S.–U.K. pharmaceutical trade," an announcement said.
Economic Impact
Drugs constitute one of the the United Kingdom's largest export categories to the America, which is easily the biggest market for leading British pharmaceutical firms.
Trade data reveal that in the one-year period prior to last September, the UK sold drugs valued at £11.1bn to the US. This figure accounted for nearly one-fifth of all goods exports in that span.
"This agreement protects employment, boosts investment and facilitates the UK to become a global hub for life sciences," the Business and Trade Secretary commented.
Specific UK Commitments
The deal involves several specific changes from the UK:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to raise overall public funding on treatments from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount drug companies must refund to the NHS to stay within budget will be capped at fifteen percent. Previously, repayments topped twenty percent.
Industry Background
This agreement comes amid a protracted dispute between the pharmaceutical industry and the UK government over drug pricing and NHS adoption.
The disagreement were exacerbated by arguments that US consumers were paying several times more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or cancelled, while substantial funding commitments have been directed toward American operations.
The Science Minister stated that the NHS must spend more on treatments, noting that its expenditure on drugs had decreased as a percentage of its overall budget over the past decade.
